Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.41 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.41 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5122289 | 0.83 | CTRB1 (0.43) | CYP3A4CYP2D6CYP2C9CYP2C19RAB9A | |
| SCHEMBL15968001 | 0.81 | CA12 (0.49) | RAB9ASMN1; SMN2POLB | |
| SCHEMBL31408077 | 0.80 | ALDH1A1 (0.45) | CYP3A4CYP2D6CYP2C9CYP2C19CASP3 | |
| SCHEMBL30891235 | 0.79 | MALT1 (0.42) | RAB9A | |
| SCHEMBL14923583 | 0.79 | MALT1 (0.42) | RAB9A | |
| SCHEMBL381668 | 0.78 | CTSL (0.50) | RAB9ACTSLCTSBCTSSMAPK1 | |
| SCHEMBL3836617 | 0.77 | CTSL (0.49) | RAB9ACTSLCTSBCTSSMAPK1 | |
| SCHEMBL16219332 | 0.77 | CTSL (0.52) | RAB9ACTSLCTSBCTSSLMNA | |
| SCHEMBL19442303 | 0.77 | CTSL (0.49) | RAB9ACTSLCTSBCTSSCTRB1 | |
| SCHEMBL12070062 | 0.77 | CTSL (0.49) | RAB9ACTSLCTSBCTSSMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763998-B1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2016-04-27 | — | — | EP | disclosed |
| US-9216997-B2 | Tri-heterocyclic derivatives, preparation process and uses thereof | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2015-12-22 | — | — | US | disclosed |
| US-9216997-B2 | Tri-heterocyclic derivatives, preparation process and uses thereof | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2015-12-22 | — | — | US | disclosed |
| US-20140329800-A1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2014-11-06 | — | — | US | disclosed |
| US-20140329800-A1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2014-11-06 | — | — | US | disclosed |
| WO-2013091502-A1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329800-A1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | MAP3K15, MAP3K1, MAP3K5 | CYP3A4 531/4885CYP2D6 792/4885CYP2C9 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.